MAPT and tauopathy: Furthermore, the discovery of both soluble and oligomeric forms of extracellular tau offers a plausible explanation for the apparent efficacy of tau antibody immunisation to slow disease progression in mouse models of tauopathy [23, 37, 44, 69].